10-Q: Mirum Pharmaceuticals Reports Q3 Net Income, Strong Revenue Growth

Mirum Pharmaceuticals, Inc. reported a net income of $2.9 million for the third quarter of 2025, driven by significant increases in product sales, particularly Livmarli and Bile Acid Medicines.

Summary

• Achieved net income of $2.9 million for the three months ended September 30, 2025, a significant improvement from a net loss of $14.2 million for the same period in 2024.
• Reported a net loss of $17.6 million for the nine months ended September 30, 2025, compared to a net loss of $64.2 million for the nine months ended September 30, 2024.
• Total revenue for the third quarter of 2025 was $133.0 million, an increase from $90.4 million in the third quarter of 2024.
• Total revenue for the nine months ended September 30, 2025, reached $372.4 million, up from $237.5 million for the same period in 2024.
• Livmarli product sales increased to $92.2 million in Q3 2025 from $59.1 million in Q3 2024, and to $253.6 million for 9M 2025 from $149.2 million for 9M 2024.
• Bile Acid Medicines sales grew to $40.8 million in Q3 2025 from $31.2 million in Q3 2024, and to $118.8 million for 9M 2025 from $87.8 million for 9M 2024.
• Unrestricted cash, cash equivalents, and investments stood at $378.0 million as of September 30, 2025, an increase from $292.8 million as of December 31, 2024.
• Accumulated deficit was $661.8 million as of September 30, 2025.
• Volixibat received FDA Breakthrough Therapy Designation for cholestatic pruritus in patients with Primary Biliary Cholangitis (PBC) in October 2024.
• The VISTAS Phase 2b clinical trial in Primary Sclerosing Cholangitis (PSC) completed enrollment in the third quarter of 2025.
• The MRM-3379 Phase 2 multi-dose safety and efficacy trial for Fragile-X Syndrome (FXS) has begun enrolling patients.
• Ctexli (chenodiol tablets) received FDA approval for the treatment of Cerebrotendinous Xanthomatosis (CTX) in adults in February 2025.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial improvement in Q3 2025, achieving net income and substantial revenue growth across its key products. Operating cash flow also improved significantly. Pipeline advancements, including a Breakthrough Therapy Designation and new trial enrollments, are positive. However, the company still carries an accumulated deficit and anticipates future net losses due to ongoing development and commercialization costs. The competitive landscape and regulatory uncertainties remain significant factors.

Positives

• Achieved net income of $2.9 million in Q3 2025, a significant turnaround from a net loss of $14.2 million in Q3 2024.
• Total revenue increased by 47.2% to $133.0 million in Q3 2025 compared to $90.4 million in Q3 2024, demonstrating strong commercial execution.
• Livmarli product sales grew by 56.0% to $92.2 million in Q3 2025, indicating robust market acceptance and demand.
• Bile Acid Medicines product sales increased by 30.8% to $40.8 million in Q3 2025, contributing to overall revenue growth.
• Unrestricted cash, cash equivalents, and investments increased to $378.0 million as of September 30, 2025, from $292.8 million at year-end 2024, strengthening liquidity.
• Net cash provided by operating activities was $49.8 million for the nine months ended September 30, 2025, a substantial improvement from $15.4 million in the prior year period.
• Volixibat received FDA Breakthrough Therapy Designation for cholestatic pruritus in PBC in October 2024, potentially accelerating its development and review.
• Ctexli (chenodiol tablets) received FDA approval for CTX in adults in February 2025 and was granted orphan exclusivity, securing market position.
• The VISTAS Phase 2b clinical trial in PSC completed enrollment in Q3 2025, moving closer to topline data.
• The MRM-3379 Phase 2 multi-dose safety and efficacy trial for FXS has begun enrolling patients, expanding the development pipeline.
• Recognized a $0.3 million benefit from income taxes in Q3 2025 due to the One Big Beautiful Bill Act (OBBBA), which eliminated the requirement to capitalize domestic research and experiment costs.

Negatives

• Incurred a net loss of $17.6 million for the nine months ended September 30, 2025, indicating ongoing overall unprofitability despite a positive Q3.
• Accumulated deficit reached $661.8 million as of September 30, 2025, reflecting historical operating losses.
• Research and development expenses increased by $11.3 million (35.5%) in Q3 2025 and $38.5 million (39.8%) for the nine months ended September 30, 2025, driven by pipeline expansion and personnel costs.
• Selling, general and administrative expenses increased by $11.4 million (22.6%) in Q3 2025 and $37.5 million (25.8%) for the nine months ended September 30, 2025, due to increased commercial activities and employee headcount.
• Interest income decreased by $0.2 million in Q3 2025 and $1.3 million for the nine months ended September 30, 2025, primarily due to lower yields on investments.
• The Phase 2b EMBARK clinical trial evaluating Livmarli in biliary atresia (BA) did not meet its primary or key secondary endpoints in December 2023, representing a setback for that indication.
• Convertible notes are convertible at the option of holders during Q4 2025, which could lead to cash settlement obligations or dilution of existing stockholders if settled in common stock.

Risks

• The success of the business depends on the ability to profitably market and sell approved medicines, which relies on growing and maintaining sales capabilities, adequate reimbursement, market acceptance, and a continued acceptable safety profile.
• Reliance on third parties for manufacturing and distribution of clinical and commercial drug supplies, including certain sole-source suppliers, poses risks of failure to obtain/maintain regulatory approval, provide sufficient quantities, or do so at acceptable quality levels or prices.
• Product candidates require significant clinical testing, which is a lengthy and expensive process with uncertain outcomes, and results of earlier studies may not be predictive of future trial results.
• Potential for delays and difficulties in enrolling patients in clinical trials, which could adversely affect clinical development activities.
• Clinical trials may fail to adequately demonstrate the safety and efficacy of product candidates, which could prevent or delay regulatory approval and commercialization.
• Approved medicines or product candidates may cause undesirable side effects or have other properties that could limit their commercial profile, expose to product liability claims, or delay/prevent regulatory approval.
• Failure to comply with reporting and payment obligations under government pricing programs (e.g., Medicaid Drug Rebate Program) could result in additional reimbursement requirements, fines, and sanctions.
• Exposure to product liability claims for approved medicines and product candidates, with potential for substantial liability if insurance coverage is inadequate.
• Risk of improper promotion of off-label uses of approved medicines or unapproved uses of product candidates, leading to prohibitions, product liability claims, and significant fines, penalties, and reputational harm.
• Approved medicines and product candidates are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and penalties for non-compliance.
• Disruptions at regulatory authorities (FDA, EMA) caused by layoffs, funding shortages, or global health concerns could negatively impact the business.
• Recently enacted legislation, future legislation, and healthcare reform measures (e.g., Inflation Reduction Act, One Big Beautiful Bill Act) may increase the difficulty and cost of obtaining marketing approval and commercializing products, and may affect pricing.
• Various risks associated with marketing product candidates internationally, including differing regulatory requirements, economic weakness, foreign currency fluctuations, and challenges enforcing intellectual property rights.
• Significant competition from other biotechnology and pharmaceutical companies with products that may directly or indirectly compete, which could adversely affect operating results.
• Inability to obtain or maintain the benefits associated with orphan drug status, including market exclusivity, which could be lost under certain conditions or due to new legislation.
• Failure to realize all anticipated benefits of commercial and product candidate acquisitions or longer-than-expected realization timelines.
• High dependence on key personnel and potential difficulties in attracting and retaining highly qualified personnel, or managing organizational growth.
• Business disruptions (e.g., natural disasters, geopolitical events, epidemics) could seriously harm future revenue and financial condition and increase costs and expenses.
• Risk that employees, independent contractors, or other third parties may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
• Dependence on intellectual property licensed from third parties; termination of any of these licenses could result in the loss of significant rights.
• Inability to obtain and maintain sufficient intellectual property protection for approved medicines and product candidates, or if the scope of protection is not sufficiently broad, competitors could develop and commercialize similar products.
• Indebtedness from convertible notes could limit cash flow available for operations, expose to risks, and impair the ability to satisfy obligations, with potential for dilution of existing stockholders upon conversion.
• Limitations on the ability to utilize net operating loss carryforwards and certain other tax attributes due to ownership changes or changes in tax laws.
• Risk of information technology systems, or those used by third parties, being compromised, leading to material adverse consequences including regulatory actions, litigation, fines, and business disruptions.
• Subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations, with potential for criminal liability and other serious consequences for violations.
• Potential for future material weaknesses in internal control over financial reporting, which could impair the ability to produce accurate financial statements on a timely basis.
• Increased costs to comply with changing laws, rules, regulations, and standards relating to corporate governance, workforce initiatives, and public disclosure.
• The trading price of common stock may be volatile, and stockholders could lose all or part of their investment due to various factors, including clinical trial results, regulatory decisions, competition, and macroeconomic developments.
• Principal stockholders and management own a significant percentage of stock and are able to exert significant control over matters subject to stockholder approval.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of stockholders and could cause the stock price to fall.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of common stock and prevent or frustrate attempts by stockholders to replace or remove current management.
• Exclusive forum provisions in the amended and restated certificate of incorporation and bylaws could limit stockholders' ability to obtain a favorable judicial forum for disputes.

Future Outlook

Mirum Pharmaceuticals anticipates continued net losses for the foreseeable future, despite achieving net income in Q3 2025, as it continues commercial activities for approved medicines, conducts ongoing and planned clinical trials, seeks regulatory approvals for product candidates, and makes potential milestone payments. The company expects total product sales of its approved medicines to increase annually, though quarterly fluctuations may occur due to large periodic orders. Research and development expenses are projected to increase with the continued development of volixibat, the Livmarli EXPAND study, and the initiation of MRM-3379 development. Selling, general and administrative expenses are also expected to rise to support commercialization efforts and global operations. The company believes its existing unrestricted cash, cash equivalents, and investments of $378.0 million as of September 30, 2025, will be sufficient to fund current operations for at least the next 12 months. Topline data for the VISTAS Phase 2b clinical trial in PSC is expected in Q2 2026, while enrollment for the VANTAGE Phase 2b clinical trial in PBC and the Livmarli Phase 3 EXPAND study is expected to complete in 2026, with topline data for both anticipated in H1 2027.

Management Comments

• "We anticipate we will continue to generate net losses for the foreseeable future as we continue commercial activities for our approved medicines, conduct our ongoing and planned clinical trials, seek regulatory approvals for our product candidates and make potential milestone payments to the licensors and other third parties from whom we have in-licensed or acquired our product candidates."
• "We expect that total product sales of our approved medicines will continue to increase on an annual basis; however, due to large periodic orders from Takeda and our distributors, our product revenue may experience fluctuations."
• "Based on our current and anticipated level of operations and cash generated from sales of our approved medicines, we believe our existing unrestricted cash, cash equivalents and investments will be sufficient to fund current operations through at least the next 12 months from the filing of this Quarterly Report on Form 10-Q and beyond."

Industry Context

Mirum Pharmaceuticals operates in the highly competitive and rapidly innovating biopharmaceutical industry, focusing on rare diseases. The company faces significant competition from major multinational pharmaceutical companies, established biotechnology firms, specialty pharmaceutical companies, and generic manufacturers. Specific competitive pressures include other IBAT inhibitors (e.g., Ipsen's odevixibat, GSK's linerixibat) for cholestatic liver diseases, as well as off-label medications and emerging gene therapies. The industry is also heavily influenced by evolving healthcare reform measures and governmental scrutiny on drug pricing and reimbursement, both in the U.S. (e.g., Inflation Reduction Act, One Big Beautiful Bill Act) and internationally (e.g., EU HTA Regulation, potential changes to market exclusivity). Geopolitical and macroeconomic developments, such as trade tensions and inflation, further impact global supply chains and financial markets, adding complexity to operations.

Comparison to Industry Standards

• Competes with GlaxoSmithKline plc (GSK) and Ipsen, which also have IBAT inhibitors in clinical development for cholestatic liver diseases.
• Ipsen's odevixibat (Bylvay/Kayfanda) is approved for pruritus in PFIC and ALGS in the U.S. and EU, serving as a direct competitor to Livmarli.
• GSK's linerixibat Phase 3 GLISTEN trial in PBC met its primary pruritus endpoint, with marketing applications submitted in H1 2025 and potential approvals in H1 2026, posing future competition in PBC.
• Off-label medications such as Ursodeoxycholic acid (UDCA), cholestyramine, rifampin, and naltrexone are commonly used in ALGS, PFIC, PSC, and PBC, representing established, lower-cost alternatives.
• In adult cholestasis, approved second-line treatments for PBC include Alfasigma's Ocaliva, Gilead Sciences' Livdelzi, and Ipsen's Iqirvo.
• Several agents are in clinical development for PBC, including Alfasigma's Ocaliva and bezafibrate, Zydus Therapeutics Inc.'s saroglitazar magnesium, Calliditas Therapeutics AB's setanaxib, and GSK's linerixibat.
• For PSC, there are no FDA or European Commission approved therapeutics, but several agents are in clinical development, such as Dr. Falk Pharma's Norucholic acid, HighTide Therapeutics Inc.'s HTD1801, and Alfasigma's Ocaliva.
• In FXS, Shionogi & Co., LTD. is pursuing clinical development of a PDE4D inhibitor (zatomilast/BPN14770), directly competing with MRM-3379.
• Other companies developing therapies for FXS include Harmony Biosciences Inc.'s ZYN002, Allos Pharma Inc.'s Arbaclofen, and Healx Ltd.'s Gabaxodol.
• Dr. Falk Pharma GmbH and Leadiant Biosciences, Inc. hold FDA Orphan Drug Designations for CTX, similar to Mirum's Ctexli.

Corporate Governance

Legal Proceedings

• Management believes there are currently no claims or actions pending against the company that could have a material adverse effect on its results of operations, financial condition, or cash flows.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings or convertible note conversions; stock price volatility; limited dividend payments; influence of principal stockholders.
• Patients: Continued access to approved medicines (Livmarli, Cholbam, Ctexli); potential for new treatments from product candidates (volixibat, MRM-3379); risks of undesirable side effects from medicines.
• Employees: Increased headcount and equity award grants; competition for skilled personnel; potential for misconduct.
• Customers (Healthcare Providers, Payors): Availability of approved medicines; impact of pricing and reimbursement policies; potential for off-label promotion scrutiny.
• Suppliers/Manufacturers: Reliance on third-party manufacturers, including sole-source suppliers; risks of supply disruption; compliance with cGMP.
• Creditors (Convertible Note Holders): Fixed interest payments; option to convert notes to cash/stock in Q4 2025; potential for restrictions on company actions due to indebtedness.

Next Steps

• Continue commercialization efforts for approved medicines (Livmarli, Cholbam, Ctexli) in the U.S., Canada, and certain European markets.
• Advance development of volixibat for PSC and PBC, with topline data for VISTAS (PSC) expected in Q2 2026 and VANTAGE (PBC) enrollment completion in 2026 and topline data in H1 2027.
• Continue development of MRM-3379 for FXS, with a Phase 2 multi-dose safety and efficacy trial currently enrolling patients.
• Complete enrollment for the Livmarli Phase 3 EXPAND label expansion study in 2026, with topline data expected in H1 2027.
• Evaluate opportunities to partner with pharmaceutical companies for commercialization in additional countries.
• Monitor and adapt to changes in healthcare legislation, regulatory policies, and market conditions.

Key Dates

Recommendation

While Mirum Pharmaceuticals demonstrated strong revenue growth and achieved net income in Q3 2025, marking a significant improvement, the company still carries a substantial accumulated deficit and anticipates continued net losses in the foreseeable future due to high R&D and commercialization costs. The pipeline shows promise with Breakthrough Therapy Designation for volixibat and ongoing trials, but these are long-term endeavors with inherent risks. The competitive landscape is intense, and regulatory changes could impact profitability. The current financial position is stable for the next 12 months, but future capital raises are likely, which could lead to dilution. Given the mix of strong commercial execution, promising but costly pipeline development, and significant industry-specific risks, a "hold" recommendation is appropriate for a seasoned investor to monitor continued execution and pipeline progress.

Keywords

Biopharmaceutical, Rare Diseases, Livmarli, Maralixibat, Cholbam, Chenodal, Ctexli, Bile Acid Medicines, Alagille Syndrome, Primary Familial Intrahepatic Cholestasis, Cholestatic Pruritus, Volixibat, Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, MRM-3379, Fragile-X Syndrome, IBAT inhibitor, PDE4D inhibitor, Clinical Trials, Regulatory Approval, FDA, EMA, Commercialization, Product Sales, Financial Results, SEC Filing, 10-Q, Biotechnology, Pharmaceutical